STE — STERIS plc

The near-term mood is clearly negative even though the fundamentals weren't: STERIS beat on Q1 FY27 adjusted EPS ($2.59 vs ~$2.50 consensus) with ~7% revenue growth, yet the stock fell ~4.9% on the print and is down 6.16% over one week and 10.92% over one month as of 2026-09-13. Investors are punishing the announced $600M North Carolina plant (largest single-site project ever), the higher FY27 capex plan, restructuring costs, and a soft AST capital-equipment line. That contrasts sharply with the sell-side, which remains a consensus Buy (12 buy / 2 hold) with targets in the $263-275 range - so the recent selling looks like sentiment and near-term optics, not a fundamental downgrade.

Revenue growth is moderating, not breaking: YoY moved from +9.9% (Sep-25 quarter) to +9.2% (Dec-25) to +7.3% (Mar-26) to +7.3% (Jun-26), a controlled deceleration consistent with the 7-8% FY27 organic guide. The bigger story is margin and earnings, which are inflecting higher: operating margin rose from ~14.5-16.5% in FY24 quarters to a 19.1% print in the Jun-26 quarter, and GAAP diluted EPS climbed from $1.79 (Jun-25) to $2.04 (Jun-26) - roughly +14% YoY - with the Mar-26 quarter at $2.24 vs $1.48 a year prior. Free cash flow is large (~$926M TTM) but lumpy due to the capex ramp (Jun-26 FCF $279.6M vs $326.4M in Jun-25; OCF $367.1M vs $420.0M). Net read: a structural margin-expansion trend and solid EPS compounding, with a genuinely mild revenue-growth deceleration that is partly an artifact of deliberate investment, not demand deterioration.

Reasonable-to-cheap. As of 2026-09-13, the TTM P/E was 25.7x, but on forward FY27 adjusted EPS of $11.206 the forward P/E is only ~18.8x - a low-end multiple for a defensive med-tech with expanding margins. PEG is ~1.0. P/S of 3.40 sits well below the 5-year average of 4.36 (the 5-year average P/E of 79.5x is distorted by earlier depressed GAAP earnings and is not usable). P/B 2.85 and EV/EBITDA 12.26x are both undemanding, and the deterministic framework itself flags the stock as 'Cheap vs. its own history' (score 88.7).

The stock is discounting the messy part of the story - the capex/restructuring ramp - rather than the parts that are working. If STERIS delivers its guided FY27 adjusted EPS of $11.10-11.30 on 7-8% revenue growth, the shares are being bought at under 19x forward with margins still expanding. That means the market is arguably underpricing a steady compounder during a self-inflicted investment phase; the risk is that capex-related cash-flow optics keep a lid on the multiple until FCF re-accelerates. The gap between 12 Buy ratings and a stock near its 52-week low ($195.14) is the tradeable tension.

As of 2026-09-13, the technical picture was oversold: RSI-14 of 26.74, price 8.06% below the 20-day SMA, 6.5% below the 50-day, and 9.16% below the 200-day, with the shares in the lower third of the $195.14-$269.44 52-week range. That is a washout, not a trend-following buy signal - 3-month return is still +1.54% but the 6-month is -1.78% and momentum has clearly broken. Implication for entry timing: this favors patient accumulation on weakness / mean-reversion bounce setups rather than chasing, and a decisive reclaim of the 20-day and 50-day averages would be the first confirmation that the selling pressure has exhausted.

• Healthcare utilization and procedure volumes staying durable, driving recurring demand for sterilization consumables, infection-prevention services, and AST contract sterilization.
• Persistent inflation and international tariffs pressuring gross margins - partially offset by pricing (+~190 bps to Q1 revenue) and factory productivity.
• Interest rates affecting the hurdle rate on STERIS's heavy capex cycle and its cost of capital, even though the defensive, low-beta profile insulates it from broader volatility.
• Hospital and ambulatory-surgery capital-equipment budgets, which are cyclical and drove the soft AST capital-sales commentary this quarter.
• Sector rotation within healthcare - med-tech multiples have de-rated broadly, and capital-equipment names are more sensitive to budget-flush timing than consumables names.

• Q2 FY2027 earnings (expected late October / early November 2026): the key test of whether margin expansion can absorb the new-facility ramp-up costs.
• Execution milestones and budget discipline on the North Carolina and Mentor, Ohio manufacturing projects - timing and cost overruns will be scrutinized.
• A recovery in AST capital-equipment sales and any hospital capital-budget flush into calendar year-end.
• Continued execution of the recently authorized $1B share repurchase program and any further guidance raises.

• The $600M North Carolina project and related capex/restructuring ramp compressing near-term free cash flow and ROIC (already a modest 8.5%) for several quarters.
• Gross-margin pressure from tariffs and inflation outpacing the company's pricing and productivity offsets.
• Continued revenue-growth deceleration (from ~10% toward ~7%) if capital-equipment demand stays soft.
• Cyclicality in hospital capital budgets and AST capital sales, which can swing quarterly results.
• Growing gap between GAAP and adjusted EPS (restructuring/amortization), making headline beats less reflective of reported profit.

STERIS is a genuinely high-quality, defensive med-tech compounder - ~7-8% organic revenue growth, operating margins expanding from the mid-teens to ~19%, double-digit EPS growth, a 4.5%-ish FCF yield, and a pristine balance sheet (D/E 0.28) - trading at ~18.8x forward earnings after an oversold, sentiment-driven drawdown. The bear case (heavy capex, restructuring, soft AST capital sales) is real but looks like a timing and optics problem during an investment phase, not structural deterioration. This is a reasonable risk/reward for a patient investor, though the framework's 'Fair Fundamentals' band and the near-term technical breakdown argue for scaling in rather than a full position right now.

Applied a justified ~21x forward P/E to FY2027 adjusted EPS of $11.206 (fair value ~$235), cross-checked with ~13x EV/EBITDA on roughly $1.85B of forward EBITDA less ~$1.17B net debt (~$235). The 21x sits above the current 18.8x forward multiple but below the analyst-implied ~24x, reflecting expanding margins and a cheap-vs-own-history setup offset by mid-single-digit-to-7% revenue growth and a still-ramping capex cycle.